Compare BIO-TECHNE Corp (TECH) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United Airlines Holdings Inc — how do they compare? BIO-TECHNE Corp trades at $72.1 (market cap $11.24B), while United Airlines Holdings Inc trades at $126.65 (market cap $40.17B). The key difference: United Airlines Holdings Inc is far larger — about 3.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| TECH | UAL | |
|---|---|---|
Market Cap | $11.24B | $40.17B |
Sector | Health | Industrials |
52-Week High | $72.29 | $136.11 |
52-Week Low | $43.31 | $85.21 |
Enterprise Value | $11.32B | $57.20B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.
The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
